"All roads lead to ubiquitin."
I joined Genentech in 2007 after completing a postdoc at Harvard Medical School in the area of mass spectrometry proteomics. Throughout my research career time, I’ve maintained a fascination with the biochemical and cellular functions of ubiquitin and its involvement in health and disease. My role as a group leader in Discovery Proteomics is to implement new technologies for studying how proteins and post-translational modifications control biological processes.
Postdoctoral fellows in my group have the opportunity to pursue independent research projects which meld mass spectrometry technologies with mechanistic biology. The majority of projects center on the biochemical functions of ubiquitin system and their regulatory roles on cellular processes.
Nature. 2014 Jun 19;510(7505):370-5.
Advances in mass spectrometry have revolutionized the study of cellular proteins, allowing us to elucidate the molecular mechanisms of disease and the effects of therapeutic agents in intricate detail. As is true across Genentech, the research in Discovery Proteomics is collaborative and multi-disciplinary, drawing on the expertise of some of the world's leading experts in biochemistry, cell biology and disease indications. By applying the leading edge technology in the area of mass spectrometry proteomics to biology's most challenging questions, we hope to make medical breakthroughs that impact the lives of patients.